To accelerate the development of anti-tumor ADC drugs, Zhenbaodao established a new company

Antibody-drug Conjugate (ADC) is a class of highly effective drugs that combine chemotherapy and immunotherapy
.
At the beginning of the 20th century, the German Nobel Prize winner Paul Ehrlich put forward the idea of ​​ADC drugs
.
Later, after the unremitting efforts of scientists, ADC drugs gradually began to make a series of breakthroughs
.
Especially after the successful application on solid tumors, the current research and development of ADC drugs has gradually entered the golden age
.
According to Nature's forecast, the global market sales of ADC drugs will exceed $16.
4 billion in the next five years
.
It is worth mentioning that, out of optimism about the market prospects, many pharmaceutical companies in China have also continued to increase their entry into the development of ADC drugs in recent years
.
On November 1, Treasure Island issued an announcement stating that it plans to establish a wholly-owned subsidiary in Hangzhou Qiantang New District, invest in the company's Hangzhou Biopharmaceutical Project, engage in the research and development of anti-tumor ADC drugs, and establish other subsidiaries and other industries
.
The planned total investment of the project is about 1.
7 billion yuan, of which about 100 million yuan will be invested in fixed assets, and about 1.
6 billion yuan will be invested in research and development within 6 years
.
Public information shows that Treasure Island is a comprehensive health and medicine enterprise with businesses in the pharmaceutical industry, traditional Chinese medicine industry, and pharmaceutical commerce
.
Traditional Chinese medicine has always been the company's main business segment.
In 2020, its related sales will reach 1.
98 billion yuan, accounting for 58.
4% of revenue
.
It is worth noting that Zhenbaodao previously stated in the semi-annual report that the company has always adhered to the core of drug research and development, production, and sales, and has gradually enriched the industrial chain structure.
Joining, is further consolidating its research, production and marketing infrastructure
.
In June of this year, Zhenbaodao invested in Terris to deploy the biological medicine track
.
It is reported that Terris has the first large-scale commercial biopharmaceutical production base in China that meets international cGMP standards.
The company has a number of biopharmaceuticals under development, mainly anti-tumor drugs.
Among them, TRS003, TRS004, and TRS005 are progressing rapidly.

.
The establishment of a wholly-owned subsidiary this time means that Zhenbaodao is continuing its deployment in anti-tumor drugs and biological drugs
.
Public information shows that there are currently two anti-tumor chemical drugs under development in Zhenbao Island and both have entered the clinical stage.
The target indications cover major cancer types such as liver cancer, stomach cancer, and breast cancer
.
According to ClinicalTrials.
gov, as of March 19, 2021, 29 ADC drug clinical trials are underway in China, and there are more than 20 domestic companies developing ADC drugs
.
But on the whole, most domestic pipelines are still in the pre-clinical development and laboratory research and development stages, and the number of entering the clinical stage is relatively small, and they are mainly concentrated in the phase I clinical stage
.
Therefore, the industry predicts that Zhenbao Island will accelerate its deployment in this field at this time, and it will usher in more development opportunities, and the future can be expected
.
However, it should be noted that the development of ADC drugs is also facing more challenges, such as a high rate of R&D failure and target aggregation
.
In this context, both Zhenbaodao and other entering companies need to be more cautious in their layout and further improve R&D efficiency in order to usher in better development
.